Romosozumab - getting there but not quite yet

摘要

In a recent study by Cosman and colleagues, romosozumab - a humanized monoclonal antibody targeting sclerostin - is shown to reduce the risk of vertebral and clinical fractures at 12 months compared with placebo. However, the low fracture risk of study participants necessitates the completion of an on-going clinical trial before romosozumab can be fully adopted into clinical practice.